Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Two Doses of Bortezomib (Btz) in Patients with Relapsed Multiple Myeloma (MM).

A. Keith Stewart, MB, ChB, Dan Sullivan, MD, Sagar Lonial, MD, Ann F. Mohrbacher, MD, Gurkamal Chatta, MD, Chaim Shustik, MD, Howard Burris, III, Michael Karol, PhD, Peter Zannikos, PhD, Donna E. Reece, MD

Blood (2006) 108 (11): 3533.

https://doi.org/10.1182/blood.V108.11.3533.3533

Published: 2006

Journal Articles

A Phase 1 Trial of STA-5312, a Microtubule Inhibitor with a Novel Binding Site, in Hematologic and Solid Malignancies.

Howard Burris, Neil Abramson, Cynthia L. Martel, Lee V. Schwartzberg, William Dooley, Matthew W. McLeod, Thomas Dahl, Matthew Sherman, Steven Limentani

Blood (2005) 106 (11): 2484.

https://doi.org/10.1182/blood.V106.11.2484.2484

Published: 2005

Journal Articles

Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL).

Anas Younes, MD, Julie M. Vose, MD, Andrew D. Zelenetz, MD, PhD, Mitchell R. Smith, MD, PhD, Howard Burris, MD, Stephen Ansell, MD, PhD, Jerry Klein, PhD, Elizabeth Kumm, MS, Myron Czuczman, MD

Blood (2005) 106 (11): 489.

https://doi.org/10.1182/blood.V106.11.489.489

Published: 2005

Journal Articles

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Azra Raza, MD, Natalie Callander, MD, Leonel Ochoa, MD, Lawrence Piro, MD, Peter Emanuel, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Howard Burris, III, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Curtain, MD, Richard Larson, MD, Shelby Young, RN, Gail L. Brown, MD

Blood (2005) 106 (11): 2520.

https://doi.org/10.1182/blood.V106.11.2520.2520

Published: 2005

Journal Articles

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Natalie Callander, MD, Jose L. Ochoa-Bayona, MD, Lawrence Piro, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Ira Oliff, MD, Howard Burris, III, MD, Anneliese Jameson, Kiran Patel, Gail L. Brown, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Emanuel, MD

Blood (2004) 104 (11): 1428.

https://doi.org/10.1182/blood.V104.11.1428.1428

Published: 2004

NARROW

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Two Doses of Bortezomib (Btz) in Patients with Relapsed Multiple Myeloma (MM).

A Phase 1 Trial of STA-5312, a Microtubule Inhibitor with a Novel Binding Site, in Hematologic and Solid Malignancies.

Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL).

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Email alerts

ASH Publications

American Society of Hematology

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Two Doses of Bortezomib (Btz) in Patients with Relapsed Multiple Myeloma (MM).

A Phase 1 Trial of STA-5312, a Microtubule Inhibitor with a Novel Binding Site, in Hematologic and Solid Malignancies.

Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL).

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only